NCT00155714撤回不适用
Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- mean pulmonary artery pressure
研究概览
简要总结
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
详细描述
Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary and secondary pulmonary arterial hypertension
排除标准
- •Unstable patients or patients with allergy to sildenafil
结局指标
主要结局
mean pulmonary artery pressure
6 min walking distance
WHO functional status
PaO2
次要结局
- cardiac output
- VO2max
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Phosphodiesterase-5 Inhibitor in Eisenmenger SyndromeEisenmenger SyndromeNCT01200732Govind Ballabh Pant Hospital28
撤回
不适用
Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older AdultsSarcopeniaNCT05458232University of Arkansas
已完成
2 期
Sildenafil for Treatment of Priapism in Men With Sickle Cell AnemiaSickle Cell DiseasePriapismNCT00940901Johns Hopkins University13
终止
3 期
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart FailureHeart FailurePulmonary HypertensionNCT01910389Carelon Research23
已完成
不适用
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary HypertensionGroup 2 Pulmonary HypertensionCpcPHNCT06350773Beni-Suef University66